| [1] |
Cerruto MA, Vianello F, D'elia C, et al. Transrectal versus transperineal 14-core prostate biopsy in detection of prostate cancer: a comparative evaluation at the same institution [J]. Arch Ital Urol Androl, 2014, 86(4): 284-287.
|
| [2] |
Chae Y, Kim YJ, Kim T, et al. The comparison between transperineal and transrectal ultrasound-guided prostate needle biopsy [J]. Korean J Urol, 2009, 50(2): 119-124.
|
| [3] |
Guo LH, Wu R, Xu HX, et al. Comparison between ultrasound guided transperineal and transrectal prostate biopsy: a prospective, randomized, and controlled trial [J]. Sci Rep, 2015, 5: 16089.
|
| [4] |
Udeh EI, OC Amu, Nnabugwu II, et al. Transperineal versus transrectal prostate biopsy: our findings in a tertiary health institution [J]. Niger J Clin Pract, 2015, 18(1): 110-114.
|
| [5] |
Olivier W, Leonie E, Marloes van der L, et al. Complications and adverse events of three magnetic resonance imaging-based target biopsy techniques in the diagnosis of prostate cancer among men with prior negative biopsies: results from the future trial, a multicentre randomised controlled trial [J]. Eur Urol Oncol, 2019, 2(6): 617-624.
|
| [6] |
Benjamin P, Rajan V, Konstantinos D, et al. Nonantibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis[J]. J Urol, 2021, 205(3): 653-663.
|
| [7] |
Abughosh Z, Margolick J, Goldenberg SL, et al. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy [J]. J Urol, 2013, 189(4): 1326-1331.
|
| [8] |
Ghafoori M, Shakiba M, Seifmanesh H, et al. Decrease in infection rate following use of povidone-iodine during transrectal ultrasound guided biopsy of the prostate: a double blind randomized clinical trial [J]. Iran J Radiol, 2012, 9(2): 67-70.
|
| [9] |
Panupong K, Wit V, Pitak S, et al. Reduction in bacteremia rates after rectum sterilization before transrectal, ultrasound-guided prostate biopsy: a randomized controlled trial [J]. J Med Assoc Thai, 2009, 92(12):1621-1626.
|
| [10] |
Melekos MD. Efficacy of prophylactic antimicrobial regimens in preventing infectious complications after transrectal biopsy of the prostate [J]. Int Urol Nephrol, 1990, 22(3): 257-262.
|
| [11] |
Sharpe JR, Sadlowski RW, Finney RP, et al. Urinary tract infection after transrectal needle biopsy of the prostate [J]. J Urol, 1982, 127(2): 255-256.
|
| [12] |
Brown RW, Warner JJ, Turner BI, et al. Bacteremia and bacteriuria after transrectal prostatic biopsy [J]. Urology, 1981, 18(2): 145-148.
|
| [13] |
Pilatz A, Dimitropoulos K, Veeratterapillay R, et al. Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis [J]. J Urol, 2020, 204(2): 224-230.
|
| [14] |
Fossati N, Karnes RJ, Boorjian SA, et al. Long-term impact of adjuvant versus early salvage radiation therapy in pt3n0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series [J]. Eur Urol, 2017, 71(6): 886-893.
|
| [15] |
Buscariollo DL, Drumm M, Niemierko A, et al. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience [J]. Pract Radiat Oncol, 2017, 7(2): e125-e33.
|
| [16] |
Meijer D, Donswijk ML, Bodar YJL, et al. Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: tumor localizations using PSMA PET/CT imaging [J]. J Nucl Med, 2021, 62(7): 961-967.
|
| [17] |
Piet O, Dries R, Karel D, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II Trial [J]. J Clin Oncol, 2018, 36(5): 446-453.
|
| [18] |
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study [J]. J Clin Oncol, 2008, 26(2): 242-245.
|
| [19] |
Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [J]. N Engl J Med, 2004, 351(15): 1502-1512.
|
| [20] |
De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J]. Lancet, 2010, 376(9747): 1147-1154.
|
| [21] |
Dieperink KB, Johansen C, Hansen S, et al. The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients [J]. Br J Cancer, 2013, 109(12): 3005-3013.
|